Category Archives: Pharmaceuticals

Two European Parkinson’s studies kick off 2018 with promising discoveries; proof to me, for example, that not all biotech worth noting come from the USA.

The News: A combination therapy made up of two neurotrophic factors has been shown in a report to reduce the degenerative effects of Parkinson’s disease, report researchers from the UPV/EHU-University… Read more »

Ablynx soars 60% on Novo’s latest hostile bid; grab a piece of this Belgian biotech because the real action’s just starting.

The News: Denmark’s Novo Nordisk A/S (Copenhagen), the world’s biggest insulin maker, went public Monday (January 8, 2018) with a €2.6-billion ($3.1 billion) bid for Belgian biotech group Ablynx NV… Read more »

French nanocap Sensorion inks deal with Aussie implant-maker Cochlear for €1.6M capital infusion, R&D collaboration. Pearl by the Mediterranean?

The News: Sensorion SA (Montpellier FRA), a tiny biotech company pioneering novel treatments for inner-ear diseases, and Cochlear Ltd. (Sydney), the global leader in implantable hearing devices, in a joint… Read more »

London-based biotech TopiVert, although invisible, intends to shake up Allergan, Shire in the huge dry-eye space.

The News: TopiVert Pharma Ltd., a clinical-stage biotechnology company developing narrow spectrum kinase inhibitors (NSKIs) for chronic inflammatory gastrointestinal (GI) and ocular diseases, has announced results from a Phase 1/2a… Read more »

From across the pond, 2017’s brightest European biotech stars; perhaps under US’s radar, but still ready to soar?

Many said good riddance to 2016 for biotech and pharma; things could only get better this year–and the European industry didn’t disappoint, says Labiotech.eu, the quintessential industry observer and news… Read more »

Tiny Scottish biotech TauRx lobs bomb into Alzheimer’s fracas with Phase 3 success.

The News: After countless failures, the race for a treatment saw obscure TauRx Therapeutics Ltd. (Aberdeen Scotland) sprint ahead as its Alzheimer’s drug candidate prevented the formation of Tau tangles that… Read more »

Pfizer, Merck’s Bavencio flop illustrative of shattered Pharma model. Is industry’s collapse just around the corner?

The News: Pfizer Inc. (NYC) and its German part­ner Merck KGaA (Darmstadt) have run into a brick wall in their race to ex­pand the mar­ket for their PD-L1 check­point inhibitor Baven­cio… Read more »